- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
- Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
- Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
- Ardelyx, Inc. Reports Employment Inducement Grants
- Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
- Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
- Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
- Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
- Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
More ▼
Key statistics
On Friday, Ardelyx Inc (ARDX:NMQ) closed at 8.72, -13.92% below its 52-week high of 10.13, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.36 |
---|---|
High | 9.13 |
Low | 7.98 |
Bid | 8.68 |
Offer | 8.74 |
Previous close | 8.72 |
Average volume | 7.26m |
---|---|
Shares outstanding | 232.69m |
Free float | 228.44m |
P/E (TTM) | -- |
Market cap | 2.03bn USD |
EPS (TTM) | -0.3038 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:15 BST.
More ▼